Shares of Pulmonx Corporation (LUNG) have gained 17.1% over the past four weeks to close the last trading session at $8.78, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15.83 indicates a potential upside of 80.3%. The mean estimate comprises six short-term price targets with a standard deviation of $1.72. While the lowest estimate of $14 indicates a 59.5% increase from the c ...

Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study Amgen to Host Webcast Investor Call on May 20, 2024 at 1:00 p.m. PT THOUSAND OAKS, Calif., May 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the treatment of adult p ...

REDWOOD CITY, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that the Compensation Committee of the Board of Directors of Pulmonx (the "Compensation Committee") granted inducement awards consisting of a non-statutory stock option to purchase 241,409 shares of common stock and a time-based restricted stock unit award for 125,870 shares of common stock on May 6, 2024 to ...

Shares of Pulmonx Corporation (LUNG) have gained 19.2% over the past four weeks to close the last trading session at $9.82, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15.33 indicates a potential upside of 56.1%.The average comprises six short-term price targets ranging from a low of $12 to a high of $18, with a standard deviation of $2.34. While the lowest estimate indicat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39562 PULMONX CORPORATION (Exact name of registrant as specified in its charter) Delaware 77-0424412 (State or other jur ...

Pulmonx Corporation (NASDAQ:LUNG) Q1 2024 Earnings Call Transcript May 1, 2024 4:30 PM ET Company Participants Elizabeth Sparicio - Investor Relations at the Gilmartin Group Steve Williamson - President & Chief Executive Officer Mehul Joshi - Chief Financial Officer Conference Call Participants Jon Young - Canaccord Rick Wise - Stifel Vik Chopra - Wells Fargo Operator Good day, and thank you for standing by. Welcome to Pulmonx Q1 2024 Earnings Conference Call. At this time, all participants are in a listen- ...

Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.42 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.28%. A quarter ago, it was expected that this company would post a loss of $0.39 per share when it actually produced a loss of $0.36, delivering a surprise of 7.69%.Over the last four quarters, the company has surpa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-39562 PULMONX CORPORATION (Exact name of registrant as specified in its charter) Delaware 77-0424412 (State or other jurisdiction of incorporation or organizati ...

© 2024 Pulmonx Corporation1 © 2024 Pulmonx Corporation | --- | --- | --- | --- | |----------------------------------------------------------------------------|-------|-------|----------------------------------------------------------------| | | | | | | Large Market | | | Broadly Reimbursed | | $12B opportunity for severe emphysema | | | In global guidelines & reimbursed in US, Europe and Australia | | | | | | | Precision Treatment | | | Global Footprint | | Proprietary patient selection technology & minimal ...

Pulmonx Corporation. (NASDAQ:LUNG) Q4 2023 Earnings Conference Call February 21, 2024 4:30 PM ET Company Participants Laine Morgan - Investor Relations, Gilmartin Group LLC Glendon French - President and Chief Executive Officer John McKune - Interim Chief Financial Officer and Vice President Corporate Controller Conference Call Participants Jason Bednar - Piper Sandler Rick Wise - Stifel Jon Young - Canaccord Operator Good day and thank you for standing by. Welcome to the Pulmonx Fourth Quarter and Full Yea ...